Skip to main content

Advertisement

Table 1 Baseline and Descriptive Characteristics

From: A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms

Group Gas Defense (n = 30) Placebo (n = 31)
Site   
   Dominican Republic 27 (90%) 27 (87%)
   Miami, FL 3 (10%) 4 (4%)
Age, Years 34.8 ± 12.5 38.2 ± 12.6
Gender   
   Female 16 (53%) 17 (55%)
   Male 14 (47%) 14 (45%)
Ethnicity   
   Hispanic 27 (90%) 28 (90%)
   Non-Hispanic 3 (10%) 3 (10%)
Race   
   Black/AA 8 (27%) 7 (23%)
   Caucasian 9 (30%) 9 (29%)
   Other 12 (43%) 15 (48%)
Height, cm 164.2 ± 8.6 165.8 ± 9.8
Weight, kg 71.4 ± 14.1 79.2 ± 19.3
Status   
   Completed Protocol 30 (100%) 30 (97%)
   Early Termination 0 (0%) 1 (3%)
Heart Rate, beats/minute 69.9 ± 12.1 70.7 ± 10.3
Systolic Blood Pressure, mm Hg 121.2 ± 17.0 122.2 ± 10.9
Diastolic Blood Pressure, mm Hg 75.1 ± 9.0 76.0 ± 7.2
GSRS - Abdominal Pain Subscore 3.17 ± 1.85 3.14 ± 1.48
GSRS - Abdominal Distension Subscore 3.38 ± 2.13 4.14 ± 1.43
GSRS - Increased Flatus Subscore 3.86 ± 1.92 4.07 ± 1.53
GSRS - Total GI Symptom Score 40.8 ± 19.8 39.4 ± 12.1
SODA - Bloating Subscore 2.52 ± 1.48 2.93 ± 1.25
SODA - Gas Subscore 3.28 ± 0.96 3.28 ± 0.84
SODA - Non-pain Symptoms Score 16.83 ± 3.35 17.00 ± 2.09
SODA - Satisfaction Score 8.3 ± 3.4 9.2 ± 3.5
SF-36v2 - Physical Component Summary 49.9 ± 8.5 49.0 ± 9.9
SF-36v2 - Mental Component Summary 51.3 ± 10.1 51.3 ± 9.9
  1. Values are expressed as mean ± standard deviation.